Do macrolide antibiotics cause Clostridioides difficile infection?

Do Macrolides Cause C. difficile Infection?

Yes, macrolides do cause C. difficile infection (CDI), though they carry a lower risk compared to other antibiotic classes like fluoroquinolones, clindamycin, and cephalosporins.

Risk Magnitude

Macrolides are definitively associated with CDI, but represent a moderate-risk antibiotic class. The IDSA/SHEA guidelines explicitly state that "virtually every antibiotic has been associated with CDI through the years" 1. When quantifying this risk:

• Community-associated CDI: Macrolides increase risk with an OR of 2.55-2.65 2, 3
• This is substantially lower than clindamycin (OR 16.80-20.43), fluoroquinolones (OR 5.50-5.65), or cephalosporins (OR 4.47-5.68) 2, 3
• However, macrolides still carry significantly higher risk than no antibiotic exposure

Mechanism and Clinical Context

Macrolides disrupt the intestinal microbiota, creating a "niche" for C. difficile to flourish 1. The risk is particularly relevant because:

• Timing matters: The highest CDI risk occurs during antibiotic therapy and in the first month after cessation (7-10 fold increase), with elevated risk persisting for 3 months 4
• Long-term, low-dose use: Chronic macrolide therapy (e.g., for respiratory conditions) poses cumulative risk. A case report documented community-acquired CDI in a child after 20 weeks of low-dose clarithromycin 5
• Strain-specific risk: Macrolide exposure specifically predicts infection with the epidemic BI/NAP1/027 strain, which shows 98% resistance to azithromycin (OR 5.2 for macrolide exposure) 6

Important Caveats

For Long-Term Macrolide Therapy

The British Thoracic Society guidelines acknowledge GI side effects occur in up to 70% of patients on erythromycin, though these "hardly ever caused study drug discontinuation" 7. However, this guideline does not specifically address CDI risk in the context of chronic respiratory disease management—a notable gap given the documented association.

Clinical Decision-Making

When prescribing macrolides:

• Avoid if possible in patients with recent CDI history (within 3 months)
• Consider lower-risk alternatives when clinically appropriate (tetracyclines showed no increased CDI risk: OR 0.91-0.92) 2, 3
• For long-term macrolide therapy in respiratory disease, counsel patients about CDI symptoms (watery diarrhea) and maintain high clinical suspicion 5
• The risk is dose- and duration-dependent: more antibiotic classes and longer exposure increase CDI risk 4

Relative Risk Hierarchy

When antibiotic therapy is necessary, the CDI risk hierarchy from highest to lowest is:

1. Clindamycin (highest risk)
2. Fluoroquinolones
3. Cephalosporins/carbapenems
4. Macrolides (moderate risk)
5. Penicillins
6. Sulfonamides/trimethoprim
7. Tetracyclines (no increased risk)

1, 2, 3

Bottom line: Macrolides absolutely cause CDI, but represent a middle-tier risk. Discontinue the inciting antibiotic immediately if CDI develops, as continued use decreases clinical response and increases recurrence 1.